John C Byrd

发表

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Guido Marcucci, Xin Wu, Fengting Yan, 2014, Cancer research.

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Sonia Jain, Feng He, Michael J Keating, 2008, Blood.

Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry

Michael A. Freitas, Guido Marcucci, Michael A Freitas, 2003, Journal of the American Society for Mass Spectrometry.

Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.

Asad Umar, J. Byrd, M. Etherton, 2004, Journal of medicinal chemistry.

The B-cell receptor signaling pathway as a therapeutic target in CLL.

J. Byrd, A. Johnson, John C Byrd, 2012, Blood.

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Amit Verma, Adrian Wiestner, Samir Parekh, 2010, Blood.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

David Jarjoura, John R Desjarlais, Bo Yu, 2010, Blood.

Genetic heterogeneity of diffuse large B-cell lymphoma

David Dunson, Ting Ni, Anjishnu Banerjee, 2013, Proceedings of the National Academy of Sciences.

Adult Burkitt leukemia and lymphoma.

Gerard Lozanski, J. Byrd, G. Lozanski, 2004, Blood.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Yuh Min Chook, David Lucas, J. Byrd, 2012, Blood.

Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.

Thomas S. Lin, M. Grever, J. Byrd, 2006, Seminars in oncology.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Juthamas Sukbuntherng, Susan O'Brien, Jeffrey A Jones, 2013, The New England journal of medicine.

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

John C Reed, Donna S Neuberg, M. Grever, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Arturo Molina, Susan O'Brien, Nyla Heerema, 2010, Blood.

Narrative Review: Initial Management of Newly Diagnosed, Early-Stage Chronic Lymphocytic Leukemia

J. Byrd, T. Shanafelt, N. Kay, 2006, Annals of Internal Medicine.

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

Guido Marcucci, Manuela Zucknick, Lianbo Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.

Guido Marcucci, Bo Yu, Jingjiao Guan, 2010, Journal of controlled release : official journal of the Controlled Release Society.

How will B-cell-receptor-targeted therapies change future CLL therapy?

Jeffrey A Jones, J. Byrd, John C Byrd, 2014, Blood.

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Arthur Weiss, Michael J Keating, Andrew W. Greaves, 2004, The New England journal of medicine.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2012, Blood.

Flavopiridol in chronic lymphocytic leukemia: a concise review.

Thomas S. Lin, M. Grever, J. Byrd, 2009, Clinical lymphoma & myeloma.

Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Claudio Agostinelli, Olivier Elemento, Fengting Yan, 2015, Blood.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Yoonjin Cho, John P Leonard, R. Ulrich, 2014, Blood.

Magnetic tweezers-based 3D microchannel electroporation for high-throughput gene transfection in living cells.

Lingqian Chang, Ratnasingham Sooryakumar, Zhaogang Yang, 2015, Small.

DNA Origami: Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model (Small 3/2016).

Comert Kural, Carlos E Castro, John C Byrd, 2016, Small.

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.

M. Grever, J. Byrd, E. Hade, 2005, Blood.